Literature DB >> 26764208

A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease.

Kevin R Kipp1, Mina Rezaei1, Louis Lin1, Elyse C Dewey1, Thomas Weimbs2.   

Abstract

Autosomal-dominant polycystic kidney disease (ADPKD) is a common cause of end-stage renal disease, and no approved treatment is available in the United States to slow disease progression. The mammalian target of rapamycin (mTOR) signaling pathway is aberrantly activated in renal cysts, and while mTOR inhibitors are highly effective in rodent models, clinical trials in ADPKD have been disappointing due to dose-limiting extrarenal side effects. Since mTOR is known to be regulated by nutrients and cellular energy status, we hypothesized that dietary restriction may affect renal cyst growth. Here, we show that reduced food intake (RFI) by 23% profoundly affects polycystic kidneys in an orthologous mouse model of ADPKD with a mosaic conditional knockout of PKD1. This mild level of RFI does not affect normal body weight gain, cause malnutrition, or have any other apparent side effects. RFI substantially slows disease progression: relative kidney weight increase was 41 vs. 151% in controls, and proliferation of cyst-lining cells was 7.7 vs. 15.9% in controls. Mice on an RFI diet maintained kidney function and did not progress to end-stage renal disease. The two major branches of mTORC1 signaling, S6 and 4EBP1, are both suppressed in cyst-lining cells by RFI, suggesting that this dietary regimen may be more broadly effective than pharmacological mTOR inhibition with rapalogs, which primarily affects the S6 branch. These results indicate that polycystic kidneys are exquisitely sensitive to minor reductions in nutrient supply or energy status. This study suggests that a mild decrease in food intake represents a potential therapeutic intervention to slow disease progression in ADPKD patients.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  ADPKD; food restriction; mTOR; polycystic kidney disease

Mesh:

Substances:

Year:  2016        PMID: 26764208      PMCID: PMC4835927          DOI: 10.1152/ajprenal.00551.2015

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  24 in total

1.  mTOR inhibitors in polycystic kidney disease.

Authors:  Terry Watnick; Gregory G Germino
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

2.  Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

Authors:  Andreas L Serra; Diane Poster; Andreas D Kistler; Fabienne Krauer; Shagun Raina; James Young; Katharina M Rentsch; Katharina S Spanaus; Oliver Senn; Paulus Kristanto; Hans Scheffel; Dominik Weishaupt; Rudolf P Wüthrich
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

3.  Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.

Authors:  Yunxia Tao; Jun Kim; Robert W Schrier; Charles L Edelstein
Journal:  J Am Soc Nephrol       Date:  2004-11-24       Impact factor: 10.121

Review 4.  AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy.

Authors:  D Grahame Hardie
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

5.  TSC2 mediates cellular energy response to control cell growth and survival.

Authors:  Ken Inoki; Tianqing Zhu; Kun-Liang Guan
Journal:  Cell       Date:  2003-11-26       Impact factor: 41.582

6.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

7.  Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

Authors:  Jonathan M Shillingford; Klaus B Piontek; Gregory G Germino; Thomas Weimbs
Journal:  J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 10.121

8.  Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease.

Authors:  K Tomobe; D Philbrick; H M Aukema; W F Clark; M R Ogborn; A Parbtani; H Takahashi; B J Holub
Journal:  J Am Soc Nephrol       Date:  1994-12       Impact factor: 10.121

9.  Folate-conjugated rapamycin slows progression of polycystic kidney disease.

Authors:  Jonathan M Shillingford; Christopher P Leamon; Iontcho R Vlahov; Thomas Weimbs
Journal:  J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 10.121

10.  Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.

Authors:  Isaline Rowe; Marco Chiaravalli; Valeria Mannella; Valeria Ulisse; Giacomo Quilici; Monika Pema; Xuewen W Song; Hangxue Xu; Silvia Mari; Feng Qian; York Pei; Giovanna Musco; Alessandra Boletta
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

View more
  32 in total

1.  Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Authors:  Godela M Brosnahan; Kaleab Z Abebe; Charity G Moore; Frederic F Rahbari-Oskoui; Kyongtae T Bae; Jared J Grantham; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Marie C Hogan; Ronald D Perrone; Dana C Miskulin; Theodore I Steinman; Vicente E Torres
Journal:  Am J Kidney Dis       Date:  2018-01-03       Impact factor: 8.860

Review 2.  Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context.

Authors:  Wouter N Leonhard; Hester Happe; Dorien J M Peters
Journal:  J Am Soc Nephrol       Date:  2016-08-04       Impact factor: 10.121

3.  Identification of targets of IL-13 and STAT6 signaling in polycystic kidney disease.

Authors:  Erin E Olsan; Jonathan D West; Jacob A Torres; Nicholas Doerr; Thomas Weimbs
Journal:  Am J Physiol Renal Physiol       Date:  2018-03-07

Review 4.  ADPKD current management and ongoing trials.

Authors:  Francesca Testa; Riccardo Magistroni
Journal:  J Nephrol       Date:  2019-12-18       Impact factor: 3.902

5.  Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.

Authors:  Jacob A Torres; Samantha L Kruger; Caroline Broderick; Tselmeg Amarlkhagva; Shagun Agrawal; John R Dodam; Michal Mrug; Leslie A Lyons; Thomas Weimbs
Journal:  Cell Metab       Date:  2019-10-17       Impact factor: 27.287

6.  Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.

Authors:  Sonu Kashyap; Kyaw Zaw Hein; Claudia Cs Chini; Jorgo Lika; Gina M Warner; Laurie K Bale; Vicente E Torres; Peter C Harris; Claus Oxvig; Cheryl A Conover; Eduardo N Chini
Journal:  JCI Insight       Date:  2020-02-27

7.  Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.

Authors:  Debbie Zittema; Irina B Versteeg; Ron T Gansevoort; Harry van Goor; Emile de Heer; Kimberley A M Veraar; Dorien J M Peters; Esther Meijer
Journal:  Am J Nephrol       Date:  2016-08-31       Impact factor: 3.754

8.  Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Authors:  Kristen L Nowak; Zhiying You; Berenice Gitomer; Godela Brosnahan; Vicente E Torres; Arlene B Chapman; Ronald D Perrone; Theodore I Steinman; Kaleab Z Abebe; Frederic F Rahbari-Oskoui; Alan S L Yu; Peter C Harris; Kyongtae T Bae; Marie Hogan; Dana Miskulin; Michel Chonchol
Journal:  J Am Soc Nephrol       Date:  2017-11-08       Impact factor: 10.121

9.  Apoptosis and autophagy in polycystic kidney disease (PKD).

Authors:  Kristen L Nowak; Charles L Edelstein
Journal:  Cell Signal       Date:  2019-12-24       Impact factor: 4.315

Review 10.  Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Fouad T Chebib; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-26       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.